DR JOANNA SEGIETH
Clinical Development, Rare Diseases
Joanna Segieth, PhD, MTOPRA is a pharmaceutical industry professional with 20+ years’ experience in drug development from major pharma/biotech organisations. A founder and director of Biosynetix, Joanna was previously a Director at Takeda and a Senior Director at UCB, leading global early and late stage asset development teams. Joanna’s focus is the design and execution of clinical development programmes linking pre-clinical findings to proof- of- mechanism and proof-of-efficacy studies in small populations with unknown infantile to adult progression characteristics. Areas of expertise and interest include orphan and pediatric drug development, advanced therapies and digital health technologies. Dr. Joanna Segieth received her PhD in Neuroscience from UCL School of Pharmacy, formerly the School of Pharmacy, Brunswick Square, London, UK, where she also completed her undergraduate degree. Joanna is a member of The Organisation for Professionals in Regulatory Affairs (TOPRA) and a key contributor to the Continuing Regulatory Education and Development (CRED) Orphan Drug Development course for TOPRA. Joanna is also an active member of Regulatory Affairs Professionals (RAPs). Joanna presents regularly at conferences as well as designing and delivering bespoke training and development material for small groups including start-ups and university lectures. Locally, Joanna is a Member of the Cambridge Rare Disease Network (CRDN) which aims to foster dialogue and awareness in order to bring active stakeholders into the rare disease space in the UK and Europe.